Abstract
AbstractBackgroundAlzheimer's disease (AD) is closely related to the loss of synapses. It has been shown that the complement system is involved in the process of synaptic elimination. We investigated whether the levels of plasma complement C3 could be a probable biomarker for the prodromal and demented AD.MethodParticipants included 58 cognitively normal (CN) subjects, 395 patients with late mild cognitive impairment (LMCI), and 112 AD patients enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database in the current study.ResultThe results showed that plasma complement C3 levels were significantly increased in AD patients compared to LMCI and CN subjects. Negative correlations between plasma complement C3 and education, MMSE were observed in all subjects.ConclusionOur findings indicate that plasma complement C3 levels may not be a valuable biomarker for the diagnosis of AD in the prodromal and dementia stages. Further studies are needed to explore the diagnostic value of plasma complement C3 based on longitudinal population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
